232 related articles for article (PubMed ID: 29524278)
21. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Datta S; Bucks ME; Koley D; Lim PX; Savinov SN
Bioorg Med Chem; 2010 Aug; 18(16):6099-108. PubMed ID: 20638853
[TBL] [Abstract][Full Text] [Related]
22. HdmX overexpression inhibits oncogene induced cellular senescence.
Miller KR; Kelley K; Tuttle R; Berberich SJ
Cell Cycle; 2010 Aug; 9(16):3376-82. PubMed ID: 20724842
[TBL] [Abstract][Full Text] [Related]
23. c-Abl phosphorylates Hdmx and regulates its interaction with p53.
Zuckerman V; Lenos K; Popowicz GM; Silberman I; Grossman T; Marine JC; Holak TA; Jochemsen AG; Haupt Y
J Biol Chem; 2009 Feb; 284(6):4031-9. PubMed ID: 19075013
[TBL] [Abstract][Full Text] [Related]
24. Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
Kallen J; Izaac A; Chau S; Wirth E; Schoepfer J; Mah R; Schlapbach A; Stutz S; Vaupel A; Guagnano V; Masuya K; Stachyra TM; Salem B; Chene P; Gessier F; Holzer P; Furet P
ChemMedChem; 2019 Jul; 14(14):1305-1314. PubMed ID: 31066983
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation.
Wang YV; Wade M; Wong E; Li YC; Rodewald LW; Wahl GM
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12365-70. PubMed ID: 17640893
[TBL] [Abstract][Full Text] [Related]
26. N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
Hayashi R; Wang D; Hara T; Iera JA; Durell SR; Appella DH
Bioorg Med Chem; 2009 Dec; 17(23):7884-93. PubMed ID: 19880322
[TBL] [Abstract][Full Text] [Related]
27. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.
Wade M; Rodewald LW; Espinosa JM; Wahl GM
Cell Cycle; 2008 Jul; 7(13):1973-82. PubMed ID: 18604177
[TBL] [Abstract][Full Text] [Related]
28. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.
Kostic M; Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
J Mol Biol; 2006 Oct; 363(2):433-50. PubMed ID: 16965791
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.
Pereg Y; Shkedy D; de Graaf P; Meulmeester E; Edelson-Averbukh M; Salek M; Biton S; Teunisse AF; Lehmann WD; Jochemsen AG; Shiloh Y
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5056-61. PubMed ID: 15788536
[TBL] [Abstract][Full Text] [Related]
30. Yin Yang 1 is a negative regulator of p53.
Sui G; Affar el B; Shi Y; Brignone C; Wall NR; Yin P; Donohoe M; Luke MP; Calvo D; Grossman SR; Shi Y
Cell; 2004 Jun; 117(7):859-72. PubMed ID: 15210108
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
32. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
33. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
[TBL] [Abstract][Full Text] [Related]
34. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.
Sosin AM; Burger AM; Siddiqi A; Abrams J; Mohammad RM; Al-Katib AM
J Hematol Oncol; 2012 Sep; 5():57. PubMed ID: 22989009
[TBL] [Abstract][Full Text] [Related]
35. The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.
Linares LK; Scheffner M
FEBS Lett; 2003 Nov; 554(1-2):73-6. PubMed ID: 14596917
[TBL] [Abstract][Full Text] [Related]
36. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
37. Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53 ubiquitination.
Bhatt P; d'Avout C; Kane NS; Borowiec JA; Saxena A
FEBS J; 2012 Feb; 279(3):370-83. PubMed ID: 22103682
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting.
Wachter F; Morgan AM; Godes M; Mourtada R; Bird GH; Walensky LD
Oncogene; 2017 Apr; 36(15):2184-2190. PubMed ID: 27721413
[TBL] [Abstract][Full Text] [Related]
39. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
